NCT05970016View on ClinicalTrials.gov

A Phase I/II Clinical Study in Patients with Advanced Solid Tumor.

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

August 7, 2023

Primary Completion Date

July 30, 2025

Study Completion Date

December 30, 2025

Conditions
Patients with Advanced Solid Tumors
Interventions
DRUG

TCC1727 tablet（1）

TCC1727 tablet will be administered orally once a day (QD) every morning for 3 days followed by discontinuation for 4 days, and 21 days/cycle on an empty stomach.

DRUG

TCC1727 tablet（2）

Drug: TCC1727 tablet TCC1727 tablet will be administered orally twice a day (BID) every morning , and 21 days/cycle on an empty stomach.

Trial Locations (1)

100000

RECRUITING

Cancer Hospital Chinese Academy of Medical Sciences, Beijing

All Listed Sponsors
lead

Beijing Tide Pharmaceutical Co., Ltd

INDUSTRY